The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Open accessAbstract
BACKGROUND: The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures. METHODS: We tested whether the results of a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-negative, tamoxifen-treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clinical trial B-14. The levels of expression of 16 cancer-related genes and 5 reference genes were used in a prospectively defined algorithm to calculate a recurrence score and to determine a risk group (low, intermediate, or high) for each patient. RESULTS: Adequate RT-PCR profiles were obtained in 668 of 675 tumor blocks. The proportions of patients categorized as having a low, intermediate, or high risk by the RT-PCR assay were 51, 22, and 27 percent, respectively. The Kaplan-Meier estimates of the rates of distant recurrence at 10 years in the low-risk, intermediate-risk, and high-risk groups were 6.8 percent (95 percent confidence interval, 4.0 to 9.6), 14.3 percent (95 percent confidence interval, 8.3 to 20.3), and 30.5 percent (95 percent confidence interval, 23.6 to 37.4). The rate in the low-risk group was significantly lower than that in the high-risk group (P<0.001). In a multivariate Cox model, the recurrence score provided significant predictive power that was independent of age and tumor size (P<0.001). The recurrence score was also predictive of overall survival (P<0.001) and could be used as a continuous function to predict distant recurrence in individual patients. CONCLUSIONS: The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray
Schena, M., Shalon, D., Davis, R. W., & Brown, P. O. (1995) · Science · doi:10.1126/science.270.5235.467 · Cited by 9,609
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Self-citationBrown, A. S., Brummel‐Smith, K., Burgess, L., D'Agostino, R. B., Goldschmidt, J. W., Halter, J. B., Hazzard, W. R., Jahnigen, D. W., Phelps, C., Raskind, M., et al. (1988) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1988.tb02362.x · Cited by 1,331
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
Singletary, S. E., Allred, C., Ashley, P., Bassett, L. W., Berry, D., Bland, K. I., Borgen, P. I., Clark, G., Edge, S. B., Hayes, D. F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.026 · Cited by 1,173
Cited by
Items 301–328 of 328
Simon, R. (2010) · Personalized Medicine · doi:10.2217/pme.09.49 · Cited by 206
Lightbody, G., Haberland, V., Browne, F., Taggart, L., Zheng, H., Parkes, E., & Blayney, J. K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby051 · Cited by 173
Tang, W., Zhou, M., Dorsey, T. H., Prieto, D. A., Wang, X. W., Ruppin, E., Veenstra, T. D., & Ambs, S. (2018) · Genome Medicine · doi:10.1186/s13073-018-0602-x · Cited by 162
Meta-analytic support vector machine for integrating multiple omics data
Kim, S., Jhong, J.-H., Lee, J., & Koo, J.-Y. (2017) · BioData Mining · doi:10.1186/s13040-017-0126-8 · Cited by 159
Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1151 · Cited by 148
Volinia, S., & Croce, C. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304977110 · Cited by 149
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
Andre, F., & Pusztai, L. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0636 · Cited by 134
A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer
Amgad, M., Hodge, J. M., Elsebaie, M. A. T., Bodelon, C., Puvanesarajah, S., Gutman, D. A., Siziopikou, K. P., Goldstein, J. A., Gaudet, M. M., Teras, L. R., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02643-7 · Cited by 137
TSPYL5 suppresses p53 levels and function by physical interaction with USP7.
Epping, M. T., Meijer, L. A. T., Krijgsman, O., Bos, J. L., Pandolfi, P. P., & Bernards, R. (2011) · Nature Cell Biology · doi:10.1038/ncb2142 · Cited by 117
Immunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
Al-Ejeh, F., Simpson, P. T., Sanus, J. M., Klein, K., Kalimutho, M., Shi, W., Miranda, M., Kutasovic, J., Raghavendra, A., Madore, J., et al. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.14 · Cited by 107
Tumor Promotion by Tumor-Associated Macrophages
Porta, C., Kumar, B. S., Larghi, P., Rubino, L., Mancino, A., & Sica, A. (2007) · Advances In Experimental Medicine And Biology · doi:10.1007/978-0-387-69116-9_5 · Cited by 95
Chu, P.-Y., Tai, Y.-L., & Shen, T.-L. (2019) · Cells · doi:10.3390/cells8050435 · Cited by 84
B-MYB Is Required for Recovery from the DNA Damage–Induced G2 Checkpoint in p53 Mutant Cells
Mannefeld, M., Klassen, E., & Gaubatz, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4156 · Cited by 82
NRF2 immunolocalization in human breast cancer patients as a prognostic factor
Onodera, Y., Motohashi, H., Takagi, K., Miki, Y., Shibahara, Y., Watanabe, M., Ishida, T., Hirakawa, H., Sasano, H., Yamamoto, M., et al. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0234 · Cited by 81
Torres-Roca, J. F. (2012) · Personalized Medicine · doi:10.2217/pme.12.55 · Cited by 81
Barriers to the Use of Personalized Medicine in Breast Cancer
Weldon, C. B., Trosman, J. R., Gradishar, W. J., Benson, A. B., & Schink, J. C. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2011.000448 · Cited by 76
Gloyeske, N. C., Dabbs, D. J., & Bhargava, R. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcp34cysatwfdpq · Cited by 63
“0) Positive nodal status,b excluding isolated tumor cells 14 (35) Nottingham grade Grade 2 4 (8) Grade 3 45 (92) PR Positive 3 (6) H-scores on PR+ cases, mean/median (range) 36/35 (3-70) HER2 status IHC score 0 or 1+ 28 (57) IHC score 2+, FISH not amplified 17 (35) IHC score 2+, FISH equivocal 4 (8) Ki-67 labeling ind…”
BackgroundRydén, L., Loman, N., Larsson, C., Hegardt, C., Vallon-Christersson, J., Malmberg, M., Lindman, H., Ehinger, A., Saal, L. H., & Borg, Å. (2018) · British Journal of Surgery · doi:10.1002/bjs.10741 · Cited by 62
Association of sleep duration and breast cancer OncotypeDX recurrence score
Thompson, C. L., & Li, L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2144-z · Cited by 58
Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy
Ji, P., Sun, W., Zhang, S., Xing, Y., Wang, C., Wei, M., Li, Q., Ji, G., & Yang, G. (2023) · Advanced Science · doi:10.1002/advs.202301789 · Cited by 57
Prediction of chemo-response in serous ovarian cancer
Gonzalez Bosquet, J., Newtson, A. M., Chung, R. K., Thiel, K. W., Ginader, T., Goodheart, M. J., Leslie, K. K., & Smith, B. J. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0548-9 · Cited by 46
HR-MAS NMR Based Quantitative Metabolomics in Breast Cancer
Gogiashvili, M., Nowacki, J., Hergenröder, R., Hengstler, J. G., Lambert, J., & Edlund, K. (2019) · Metabolites · doi:10.3390/metabo9020019 · Cited by 44
Bombard, Y., Rozmovits, L., Trudeau, M., Leighl, N. B., Deal, K., & Marshall, D. A. (2014) · Current Oncology · doi:10.3747/co.21.1782 · Cited by 30
Wang, Y. K., Print, C. G., & Crampin, E. J. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-102 · Cited by 28
Sparano, J. A., Goldstein, L. J., Childs, B. H., Shak, S., Brassard, D., Badve, S., Baehner, F. L., Bugarini, R., Rowley, S., Perez, E. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3357 · Cited by 22
Self-citationFusion of nonclinical and clinical data to predict human drug safety
Johnson, D. E. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.3 · Cited by 9
Shamai, G., Cohen, S., Binenbaum, Y., Sabo, E., Cretu, A., Mayer, C., Barshack, I., Goldman, T., Bar-Sela, G., Polónia, A., et al. (2025) · doi:10.1101/2025.05.15.25327686 · Cited by 3
Metadata
- Authors
- Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., Hiller, W., Fisher, E. R., Wickerham, D. L., Bryant, J., & Wolmark, N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-12-30
- Volume
- 351
- Issue
- 27
- Pages
- 2817-2826
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2105882193
- Cited by
- 6,277
- References
- 28
- FWCI
- 85.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.